<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Good Manufacturing Practice &#8211; UF Innovate</title>
	<atom:link href="https://innovate.research.ufl.edu/tag/good-manufacturing-practice/feed/" rel="self" type="application/rss+xml" />
	<link>https://innovate.research.ufl.edu</link>
	<description>Building business on innovation</description>
	<lastBuildDate>Tue, 12 Aug 2025 04:47:58 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://innovate.research.ufl.edu/wp-content/uploads/favicon-blue_1.png</url>
	<title>Good Manufacturing Practice &#8211; UF Innovate</title>
	<link>https://innovate.research.ufl.edu</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement To Support ONP-002 Clinical Development</title>
		<link>https://innovate.research.ufl.edu/oragenics-manufacturing-agreement-with-sterling-pharma-solutions/</link>
		
		<dc:creator><![CDATA[sooyoungryu]]></dc:creator>
		<pubDate>Thu, 17 Jul 2025 00:00:00 +0000</pubDate>
				<category><![CDATA[Accelerate]]></category>
		<category><![CDATA[News Brief]]></category>
		<category><![CDATA[UF Innovate]]></category>
		<category><![CDATA[GMP]]></category>
		<category><![CDATA[Good Manufacturing Practice]]></category>
		<category><![CDATA[intranasal therapeutics]]></category>
		<category><![CDATA[ONP-002]]></category>
		<category><![CDATA[Oragenics]]></category>
		<category><![CDATA[Sterling Pharma Solutions]]></category>
		<guid isPermaLink="false">https://scaddev1.com/oragenics-manufacturing-agreement-with-sterling-pharma-solutions/</guid>

					<description><![CDATA[UF Innovate &#124; Accelerate graduate Oragenics, Inc., has announced a manufacturing agreement with Sterling Pharma Solutions, a leading U.S.-based CDMO with multiple development and production facilities.]]></description>
										<content:encoded><![CDATA[
<p>Oragenics, Inc., a biotechnology company developing intranasal therapeutics for brain-related conditions, announced it has entered into a manufacturing agreement with Sterling Pharma Solutions, an industry-leading CDMO with multiple US-based development and manufacturing facilities. Oragenics has partnered with Sterling Pharma Solutions for the GMP production of its lead drug candidate, ONP-002, for the treatment of concussion.</p>



<p>This agreement is expected to ensure Good Manufacturing Practice (GMP)-compliant drug product supply ahead of the planned Phase IIb clinical trials which the Company expects to start next year. The collaboration marks an important milestone for Oragenics as it secures domestic production capabilities to support its upcoming clinical and regulatory efforts.</p>



Read more about <a href="https://www.globenewswire.com/news-release/2025/07/16/3116417/0/en/Oragenics-Inc-Announces-U-S-Based-Drug-Manufacturing-Agreement-to-Support-ONP-002-Clinical-Development.html"> Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement To Support ONP-002 Clinical Development.</a>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
